Brief: Zelluna Announces Preclinical Data For Lead Candidate Zi-Ma4-1
16/12/2025 11:43
Dec 16 (Reuters) - Zelluna ASA ZLNA.OL: ANNOUNCES PRECLINICAL DATA FOR LEAD CANDIDATE ZI-MA4-1 DATA SUPPORT COMPANY'S PLAN TO START CLINICAL TRIALS IN 2026 PLANS TO SUBMIT ITS CLINICAL TRIAL APPLICATION (CTA) IN LATE 2025 Source text: ID:nGNEc2nRyw Further company coverage: ZLNA.OL (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Zelluna ASA
See all newsNorway's Zelluna ASA reports Q2 loss
Brief: Zelluna Reports Q2 Total Loss Of NOK 19.7 Million
Brief: Zelluna Says IDMC Recommends Recruitment Of Next Two Patients At First Dose Level
Brief: Zelluna Says First Patient Dosed With Zi-Ma4-1 In Zima-101 Phase 1 Trial
Brief: Zelluna Wins NOK 16 Mln Research Council Of Norway Grant